Trial to Reduce IDDM in the Genetically at Risk- study
Trial to Reduce IDDM in the Genetically at Risk- study
批准号:
7647429
负责人:
Mikael Knip
金额:
$243.88万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-26 至 2011-06-30
关键词:
10 year old6 year oldAchievementAddressAdverse eventAffectAgeAliquotAllelesAmericanAncillary StudyAnimalsAntibodiesAutoantibodiesAutoimmune DiabetesAutoimmunityAwardBeta CellBlood specimenBreast FeedingCaseinsCatalogingCatalogsCattleCellsChildClinicalClinical Trials DesignClinical Trials NetworkComplexConsensusControlled Clinical TrialsCountryDNADataData CollectionDevelopmentDiabetes MellitusDiabetes preventionDietDietary InterventionDietary ProteinsDouble-Blind MethodDropsEnrollmentEnvironmentEuropeanEvolutionExclusive BreastfeedingExposure toExtravasationFamilyFirst Degree RelativeFollow-Up StudiesFoodFrequenciesFundingFunding AgencyFutureGenerationsGeneticGenetic PolymorphismGenotypeGoalsGrantHealth Insurance Portability and Accountability ActHealth PolicyHumanHuman MilkHydrolysisImmunityIncidenceIndividualInfantInfectionInstitutionInsulin-Dependent Diabetes MellitusInternationalInterventionIntervention TrialIntestinesLanguageLifeLinkLogisticsLymphocyteManualsMeasurementMeasuresMetabolicMetabolismMilkMilk ProteinsModificationMonitorMothersMulticenter TrialsNatural HistoryNeonatal ScreeningNewborn InfantOnline SystemsPeer ReviewPeripheral Blood Mononuclear CellPhasePhase I Clinical TrialsPilot ProjectsPlacebo ControlPrediabetes syndromePregnancyPreparationPrimary PreventionProceduresProgress ReportsProteinsProtocol ComplianceProtocols documentationPublic HealthQuality ControlQuestionnairesRandomizedRandomized Controlled TrialsRecruitment ActivityRelative RisksResearch DesignResearch Ethics CommitteesResearch InfrastructureResearch PersonnelRiskRodentRodent ModelRoleSamplingSecureSelf ToleranceSerumShippingShipsSocietiesStagingStatistical Data InterpretationSystemT-LymphocyteTestingTimeTrainingTranslatingTreatment EfficacyUnited States National Institutes of HealthVisitVitamin DWeaningWorkbasecasein hydrolysatecohortcrosslinkdata managementdesigndiabetes riskdisorder riskfollow-upindexingisletmeetingspreventprospectivereceptorrepositoryresponseserological markerweb site
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The Trial to Reduce Insulin Dependent Diabetes in the Genetically at Risk ('TRIGR') will determine whether weaning to a formula in which (foreign) proteins have been extensively hydrolysed, reduces disease risk for Type 1 Diabetes (T1D) in genetically susceptible children, as it does in rodent models. The Specific Aims are: I-a: To determine whether weaning to a hydrolysed casein formula (Nutramigen(tm)) reduces the frequency of diabetes-predictive autoantibodies, and I-b: To determine whether weaning to casein hydrolysate reduces the frequency of clinical diabetes. This double blind, randomized controlled trial in subjects with an affected first degree relative and risk-associated HLA genotypes, requires 2032 eligible infants: 4516 newborn babies need to be recruited, 45% of which will have eligible HLA genotypes (45.2% to date). An international, multicenter consortium has been developed comprising 73 centers in 15 countries. By the end of January'05 we achieved 65% of the recruitment target with 3187 infants registered, 2775 randomized and 1186 eligible infants entered into the intervention . The 6-8 month intervention is designed to compare the effects of either hydrolysed casein or standard cow milk based weaning formula. Duration of breast feeding is at the mothers' discretion. Recruitment and intervention will be completed by the second year of this proposal for trial continuation. All subjects are followed during and after the intervention period for 10 years with measurements of serological markers of intact cow milk exposure, diabetes predictive autoantibodies (the end point at age 6 years) and the clinical and/or metabolic indices of diabetes (the end point at age 10 years). A large, cross-linked repository of stored sera, DNA and cryopreserved peripheral blood mononuclear cells allows independently funded ancillary and mechanistic studies related to the natural history of prediabetes and the hypothesis to be tested. Cow milk protein is the most common intact foreign weaning protein in humans. If our intervention is effective in delaying autoimmunity or its progression to diabetes, this first ever primary prevention study of T1D, will have far-reaching impact for individuals and the global society.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity: Potential M
-
批准号:8241180
-
项目类别:
-
资助金额:$185.19万
-
财政年份:2012
-
负责人:Mikael Knip
-
依托单位:
Identification of Biomarkers of Autoimmunity in T1D by Novel Tools
-
批准号:7224767
-
项目类别:
-
资助金额:$13.5万
-
财政年份:2006
-
负责人:Mikael Knip
-
依托单位:
Identification of Biomarkers of Autoimmunity in T1D by Novel Tools
-
批准号:7295791
-
项目类别:
-
资助金额:$13.11万
-
财政年份:2006
-
负责人:Mikael Knip
-
依托单位:
Trial to Reduce IDDM in the Genetically at Risk -study
-
批准号:8044904
-
项目类别:
-
资助金额:$220.21万
-
财政年份:2001
-
负责人:Mikael Knip
-
依托单位:
Trial to Reduce IDDM in the Genetically at Risk -study
-
批准号:8474713
-
项目类别:
-
资助金额:$209.42万
-
财政年份:2001
-
负责人:Mikael Knip
-
依托单位:
Trial to Reduce IDDM in the Genetically at Risk -study
-
批准号:8298461
-
项目类别:
-
资助金额:$219.01万
-
财政年份:2001
-
负责人:Mikael Knip
-
依托单位:
Trial to Reduce IDDM in the Genetically at Risk -study
-
批准号:8869012
-
项目类别:
-
资助金额:$220.19万
-
财政年份:2001
-
负责人:Mikael Knip
-
依托单位:
Trial to Reduce IDDM in the Genetically at Risk- study
-
批准号:7885596
-
项目类别:
-
资助金额:$287.6万
-
财政年份:2001
-
负责人:Mikael Knip
-
依托单位:
Trial to Reduce IDDM in the Genetically at Risk- study
-
批准号:7468070
-
项目类别:
-
资助金额:$250.16万
-
财政年份:2001
-
负责人:Mikael Knip
-
依托单位:
海外基金